Sign up to receive Dana-Farber Spotlight, our email newsletter.View the current issueSubscribe nowUnsubscribe from mailings
Ellen BerlinDirector of Media Relations617email@example.com
Molly McHaleAssociate Director of Media Relations617firstname.lastname@example.org
Dr. Harold Burstein commented on a new study that found among women with operable hormone-receptor-negative breast cancer, who were given goserelin (Zoladex) in addition to chemotherapy, had lower rates of ovarian failure and higher rates of pregnancy compared with patients treated with chemotherapy alone.
Dr. Craig Bunnell discussed Dana-Farber’s new plan to implement next day appointments with an oncologist for newly diagnosed patients.
Drs. Susan Block, Atul Gawande and Rachelle Bernacki were mentioned for the randomized study performed at Dana-Farber examining how closely the wishes of a group of the sickest patients are honored during end-of-life care.
Dr. Anthony Letai led a study showing a new technique that can predict which specific drug will be most effective in treating various types of cancer tumors.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: